80 results about "Cervical cancer screening" patented technology

Uterine cervical cancer Computer-Aided-Diagnosis (CAD) according to this invention consists of a core processing system that automatically analyses data acquired from the uterine cervix and provides tissue and patient diagnosis, as well as adequacy of the examination. The data can include, but is not limited to, color still images or video, reflectance and fluorescence multi-spectral or hyper-spectral imagery, coherent optical tomography imagery, and impedance measurements, taken with and without the use of contrast agents like 3-5% acetic acid, Lugol's iodine, or 5-aminolevulinic acid. The core processing system is based on an open, modular, and feature-based architecture, designed for multi-data, multi-sensor, and multi-feature fusion. The core processing system can be embedded in different CAD system realizations. For example: A CAD system for cervical cancer screening could in a very simple version consist of a hand-held device that only acquires one digital RGB image of the uterine cervix after application of 3-5% acetic acid and provides automatically a patient diagnosis. A CAD system used as a colposcopy adjunct could provide all functions that are related to colposcopy and that can be provided by a computer, from automation of the clinical workflow to automated patient diagnosis and treatment recommendation.

The invention discloses a composition and reagent kit for early cervical cancer detection. The composition comprises 3 CpG island regions subjected to high methylation in an EPB41L3 gene and 3 CpG island region amplifying primers subjected to high methylation in a JAM3 gene, 98% or above of different types of cervical cancer can be covered, and detection of polygene polymethylation regions can berealized through a one-pipe reaction and detection. A specific MGB probe and a degenerate closed primer are preferably selected for cooperation, so that sensitivity and accuracy are further increased.The whole detection process is free from wounds, simple and convenient to operate and easy to interpret, universal qPCR equipment can meet detection, a wholly-closed form is adopted in the PCR process, and the possibility of cross-contamination can be avoided; besides, three segments of two markers are detected at the same time, so that the result is more accurate; and all the factors are integrated, so that the composition disclosed by the invention has social promotion properties. Due to high sensitivity of detection, the composition is suitable for non-invasive early cervical cancer screening.

The present invention relates to in vitro methods of screening human subjects for the presence of human papillomavirus (HPV) which exhibits loss of regulation of E6 / E7 mRNA expression and loss of replication and / or expression of a stabilized pre-mRNA encoding full length E6 protein. In particular, the invention provides in vitro methods of screening for persistent cell abnormalities or persistent CIN III lesions, cancer in situ or high-grade squamous intraepithelial lesions (HSIL). The methods are useful in the context of cervical cancer screening.

The invention provides an artificial intelligence cervical cancer screening determination method and device. The artificial intelligence cervical cancer screening determination method includes the steps: obtaining first user information; obtaining a first medical record according to the first user information; obtaining pre-diagnosis information of the first user, wherein the pre-diagnosis information includes cervical cancer information; obtaining the menopause date of the user according to the first medical record; determining whether the menopause date satisfies a first predetermined condition; obtaining a first result when the first predetermined condition is satisfied; and determining a second result based on the pre-diagnosis information and the first result, wherein the second result represents the probability of suffering from cervical cancer for the first user. The artificial intelligence cervical cancer screening determination method solves the technical problems that in theprior art, manual detection is required, and many factors that are subject to human influence exist, and the medical data of the patient is fragmented, thus being not conducive to data analysis. The artificial intelligence cervical cancer screening determination method achieves system integration of the patient data, thus being beneficial to management analysis, and the analysis process is completed automatically, without human factors, thus achieving technical effect with higher reliability.

Methods of predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion are provided. Aspects of the methods include obtaining both morphometric and biomarker data from a liquid cervical cellular sample and then using both types of data to predict whether the subject has a CIN lesion. Also provided are systems that find use in practicing the methods. The methods and systems find use in a variety of applications, including cervical cancer screening applications.

The invention relates to a cervical cancer precancerous lesion screening method combining spectrums and images, and belongs to the field of spectral analysis and medical image processing. The method comprises the following steps: constructing a database according to spectrum and image data collected by a spectrum and endoscope combined probe at the same time, constructing a neural network precancerous lesion classification model by using the spectrum database, displaying the spectral diagnosis results of corresponding detection points on the images of the corresponding detection points by using different colors by utilizing image registration and fusion, reconstructing a precancerous lesion distribution diagram, and outputting the diagnosis results according to the distribution diagram. The method can be independently used as a cervical cancer screening algorithm, and can also provide image guidance for further biopsy. The diagnosis result of the method is the cervical cancer precancerous lesion distribution diagram which is objective and direct and not influenced by the technology of operators.

The invention provides a cervical carcinoma screening method which employs an improved Pap smear for screening. The method comprises the steps: extracting uterine neck secretion, performing conventional staining, film reading and diagnosis; if a patient is diagnosed as ASCUS or a more serious disease by improved Pap smear in cytologic level, performing pathology biopsy under iodine staining inspection. The invention also provides a cervical carcinoma two-method combined screening method. The method comprises: acquiring uterine neck secretion by improved Pap smear, immediately employing an acetic-acid naked-eye inspection method for screening: if a patient is diagnosed as positive by the acetic-acid naked-eye inspection method, performing pathology biopsy at once; and if a patient is diagnosed as negative, waiting for a diagnosis result of the improved Pap smear on site, if the patient is diagnosed as ASCUS or a more serious disease by the improved Pap smear, performing pathology biopsy at once. The methods provided by the invention employ two, but not one, methods for screening on women at the same time, which is not achieved before the methods provided by the invention are disclosed. The methods provided by the invention help to improve detection rate of cervical precancerous lesion and early-stage cancer.

The invention discloses a method of detecting a human papilloma virus 16 / 18 type gene in urine by using digital PCR (polymerase chain reaction). The method comprises the particular steps of extracting DNA (deoxyribonucleic acid) from the urine, preparing a primer reaction solution, preparing a droplet, performing PCR amplification, detecting the droplet, analyzing data and displaying a result, wherein a lysate comprises 10mM of Tris-HCl, 1mM of EDTA (ethylene diamine tetraacetic acid) and 0.5% of SDS (sodium dodecyl sulfonate); a pH (potential of hydrogen) value of a sodium acetate solution is 5.2. The detection mode is free from age limit and available; sampling is noninvasive; the method has high sensitivity and high precision and overcomes the detection difficulty arising from little viral nucleic acid in the urine; HR-HPV detection in the urine can be widely applied to clinical diagnosis and treatment and cervical cancer screening; the method has the advantage that the method has an important significance for prevention and treatment of a cervical cancer.

The invention discloses a rapid cervical cancer screening system and method. The system comprises a handheld device and a host in communication connection with the handheld device. The handheld deviceis provided with a first electrode pair used as excitation electrodes to generate current signals, a second electrode pair used as measuring electrodes to detect impedance, a light source and a detector. The host comprises a control module and a data processing module, the control module is used for controlling the handheld device, and the data processing module is used for processing detection data of the handheld device to obtain a detection result. According to the method, normal cervical tissues are distinguished from cancerous cervical tissues by detecting the difference of the normal cervical tissue and the cancerous cervical tissue in electrical and optical properties. According to the invention, electrical detection is conducted on the cervical tissue, optical detection is combined to serve as compensation, rapid screening of cervical cancer can be achieved according to the difference of electrical and optical characteristics of normal cervical tissue and abnormal cervical tissue, and the accuracy of diagnosis results can be improved.

The invention discloses a methylation site for cervical cancer screening. The methylation site is a cg24575234 site of a CHRM2 gene, a cg06818777 site of a CHAD gene, a cg08361126 site of an FGF10 gene, and a cg08976810 site of an ITGA8 gene. The invention also discloses a primer pair included in a kit for detecting a methylation level of a sample gene of cervical cancer. According to the invention, a whole process can be automated, the result is objective and is easy to interpret, and the influence of subjective factors is avoided; and the specificity of the methylation site, provided by theinvention, for detecting and screening cervical cancer is 100%, which is greater than the specificity (80%) of an HPV gene detection method, and the positive prediction value is increased from 0.0474%to 100%, so that the screening result is objective and is easy to interpret. The methylation site provided by the invention can also be used in parallel with a current cervical cancer screening experiment, thereby greatly saving the examination cost and avoiding economic losses and psychological burdens of too many false positive patients due to positive results.